XOMA (US) LLC

Type: Company
Name: XOMA (US) LLC
First reported Apr 18 2014 - Updated Apr 18 2014 - 1 reports

Insider Selling: John Varian Unloads 10,000 Shares of XOMA Corp Stock (XOMA)

XOMA Corp (NASDAQ:XOMA) CEO John Varian sold 10,000 shares of the company’s stock in a transaction that occurred on Tuesday, April 15th. The shares were sold at an average price of $4.06, for a total value of $40,600.00. Following the sale, the chief ... [Published American Banking News - Apr 18 2014]
First reported Apr 15 2014 - Updated Apr 15 2014 - 1 reports

Short Interest in XOMA Corp Expands By 43.2% (XOMA)

XOMA Corp (NASDAQ:XOMA) saw a significant increase in short interest during the month of January. As of March 31st, there was short interest totalling 9,384,397 shares, an increase of 43.2% from the March 14th total of 6,552,758 shares, AmericanBankingNews.com ... [Published American Banking News - Apr 15 2014]
First reported Apr 10 2014 - Updated Apr 10 2014 - 1 reports

Anthera Pharmaceuticals Announces Personnel Changes

By a News Reporter-Staff News Editor at Biotech Week -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company focused on developing and commercializing products to treat autoimmune diseases, announced the appointment of Steven Engle ... [Published HispanicBusiness.com - Apr 10 2014]
First reported Apr 03 2014 - Updated Apr 03 2014 - 1 reports

Anthera Pharmaceuticals : Reports Personnel Changes

Anthera Pharmaceuticals, Inc. , a biopharmaceutical company focusing on developing and commercializing products to treat autoimmune diseases, announced the appointment of Steven Engle to and the departure of Dr. James Healy , MD, PhD from its Board of ... [Published 4 Traders - Apr 03 2014]
First reported Apr 01 2014 - Updated Apr 02 2014 - 1 reports

PRE 14A - XOMA Corp (0000791908) (Filer)

Document Format FilesSeq Description Document Type Size 1 PRELIMINARY PROXY STATEMENT d701277dpre14a.htm PRE 14A 662920 2 GRAPHIC g701277g74c33.jpg GRAPHIC 7704 Complete submission text file 0001193125-14-126311.txt 674818 ... [Published SEC - Apr 01 2014]
Entities: XOMA (US) LLC
First reported Apr 01 2014 - Updated Apr 01 2014 - 1 reports

XOMA Shares Down 17.9% Since SmarTrend's Sell Call (XOMA)

SmarTrend identified a Downtrend for XOMA (NASDAQ:XOMA) on March 6th, 2014 at $6.75. In approximately 4 weeks, XOMA has returned 17.93% as of today's recent price of $5.54. ... [Published Individual.com - Apr 01 2014]
Entities: XOMA (US) LLC, Stocks
First reported Mar 31 2014 - Updated Mar 31 2014 - 1 reports

ANTHERA PHARMACEUTICALS : Announces Personnel Changes

/PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company focused on developing and commercializing products to treat autoimmune diseases, today announced the appointment of Steven Engle to and the departure of Dr. James ... [Published 4 Traders - Mar 31 2014]
First reported Mar 27 2014 - Updated Mar 27 2014 - 1 reports

XOMA Corp Receives Consensus Rating of “Hold” from Analysts (NASDAQ:XOMA)

XOMA Corp (NASDAQ:XOMA) has been given a consensus rating of "Hold" by the ten ratings firms that are presently covering the stock, AnalystRatings.Net reports. One research analyst has rated the stock with a sell rating, two have assigned a hold rating ... [Published American Banking News - Mar 27 2014]
First reported Mar 25 2014 - Updated Mar 25 2014 - 1 reports

These Stocks Are Getting Hit Hardest During March's Biotech 'Correction'

A list that might be interesting only to me, but I will share anyway: The biotech and drug stocks getting hit the hardest during the biotech correction -- or whatever you want to call it:Tops on the list is Geron , down 58% in March.GERN data by YCh ... [Published Joshua Star - Mar 25 2014]
First reported Mar 25 2014 - Updated Mar 25 2014 - 1 reports

XOMA Down 17.5% Since SmarTrend Downtrend Call (XOMA)

SmarTrend identified a Downtrend for XOMA (NASDAQ:XOMA) on March 6th, 2014 at $6.75. In approximately 3 weeks, XOMA has returned 17.48% as of today's recent price of $5.57. ... [Published Individual.com - Mar 25 2014]
Entities: XOMA (US) LLC
First reported Mar 19 2014 - Updated Mar 20 2014 - 18 reports

Healthcare Companies Report Financial Results, Partnerships, and Recognitions - Analyst Notes on Keryx, WellCare, Zogenix, Orexigen Therapeutics, and XOMA

SOURCE Analysts ReviewEditor Note: For more information about this release, please scroll to bottom.NEW YORKToday, Analysts Review released its analysts' notes regarding Keryx Biopharmaceuticals Inc. (NASDAQ: KERX), WellCare Health Plans, Inc. (NYSE: ... [Published ABC 3340 - Mar 19 2014]
First reported Mar 05 2014 - Updated Mar 05 2014 - 2 reports

Why XOMA Corporation (XOMA) Is Plunging Today

NEW YORK (TheStreet) -- XOMA Corporation  was plunging 25% to $7.08 at 10:26 a.m. on Wednesday after the biotechnology company announced that it would not move forward with late-stage testing of its drug gevokizumab as a treatment for a form of arthritis ... [Published The Street Latest - Mar 05 2014]

Quotes

...Christopher S Henney , Chairman of Anthera Pharmaceuticals . "We look forward to taking advantage of his insight as we further advance Anthera's clinical programs."
...had tears in their eyes, as Scannon closed the ceremony by reciting a passage from " For the Fallen ," a World War I poem by Laurence Binyon: "They shall not grow old, as we that are left grow oldold Age shall not weary them, nor the years condemn. / At the going down of the sun and in the morning / We will remember them."

More Content

All (75) | News (49) | Reports (0) | Blogs (8) | Audio/Video (0) | Fact Sheets (1) | Press Releases (16)
sort by: Date | Relevance
Anthera Pharmaceuticals Announces Personnel Cha... [Published OrbiMed Advisors - 10 hours ago]
Dermatological Drugs Market Forecast 2014-2024 [Published Individual.com - Apr 22 2014]
How BentProp and undersea robots found long-los... [Published CNET News - Apr 20 2014]
Insider Selling: John Varian Unloads 10,000 Sha... [Published American Banking News - Apr 18 2014]
Global Hypertension Drugs Market 2014-2018 [Published MarketResearch.com - Apr 15 2014]
Short Interest in XOMA Corp Expands By 43.2% (X... [Published American Banking News - Apr 15 2014]
WEEKLY PORTFOLIO UPDATE: HOW LOW WILL WE GO? [Published Seeking Alpha - Apr 13 2014]
Anthera Pharmaceuticals Announces Personnel Cha... [Published HispanicBusiness.com - Apr 10 2014]
Pacira Pharmaceuticals Inc. (NASDAQ:PCRX) Rides... [Published Live Trading News - Apr 08 2014]
2018 Worldwide Hypertension Drugs Market : Size... [Published PitchEngine - Apr 08 2014]
Anthera Pharmaceuticals : Reports Personnel Cha... [Published 4 Traders - Apr 03 2014]
PRE 14A - XOMA Corp (0000791908) (Filer) [Published SEC - Apr 01 2014]
XOMA Shares Climbing Higher, Up 6.3% [Published Individual.com - Apr 01 2014]
XOMA Shares Down 17.9% Since SmarTrend's Sell C... [Published Individual.com - Apr 01 2014]
ANTHERA PHARMACEUTICALS : Announces Personnel C... [Published 4 Traders - Mar 31 2014]
XOMA Corp Receives Consensus Rating of “Hold” f... [Published American Banking News - Mar 27 2014]
These Stocks Are Getting Hit Hardest During Mar... [Published Joshua Star - Mar 25 2014]
XOMA Down 17.5% Since SmarTrend Downtrend Call ... [Published Individual.com - Mar 25 2014]
Shares of XOMA Under Pressure, Down 10.1% [Published Comtex SmarTrend - Mar 24 2014]
Abraxas Petroleum Corp. (AXAS), CAMAC Energy In... [Published 4 Traders - Mar 22 2014]
XOMA Corp Shares Down 5.8% After Insider Sell... [Published American Banking News - Forex - Mar 21 2014]
XOMA Corp CMO Unloads $111,365 in Stock (XOMA) [Published American Banking News - Mar 20 2014]
XOMA Corp VP Patrick J. Md Phd Scannon Sells 3,... [Published American Banking News - Mar 20 2014]
XOMA Corp CFO Fred Kurland Sells 5,915 Shares (... [Published American Banking News - Mar 20 2014]
Healthcare Companies Report Financial Results, ... [Published ABC 3340 - Mar 19 2014]
Healthcare Companies Report Financial Results, ... [Published WNEM - Mar 19 2014]
Healthcare Companies Report Financial Results, ... [Published KWQC - Mar 19 2014]
Healthcare Companies Report Financial Results, ... [Published WOWK - Mar 19 2014]
Healthcare Companies Report Financial Results, ... [Published KCEN HD - Mar 19 2014]
Healthcare Companies Report Financial Results, ... [Published WSFX-TV - Mar 19 2014]
1 2 3
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Xoma to stop testing drug as arthritis treatmen... [Published Yahoo! Health News - Mar 05 2014]
United States drug developer Xoma Corp said it would not proceed with late-stage studies of its lead drug, an antibody called gevokizumab, as a treatment for a form of arthritis of the hand after two mid-stage studies showed the drug was not effec... ...
XOMA Suffers Big Setback [Published Wall St. Cheat Sheet - Mar 05 2014]
While many biotechnology stocks have been generating impressive returns of late, one stock suffered a major setback on Tuesday evening. That company is XOMA Corporation ( NASDAQ:XOMA ). XOMA Corporation is a biotechnology company focused on the ...
Frontrunning: March 5 [Published Zero Hedge - Mar 05 2014]
High Stakes Limit Bid to Cow Putin ( WSJ ) Russia says can't control Crimea troops ahead of U.S. talks ( Reuters ) Crimea Crisis Haunted by Ghosts of Bungled World War I Diplomacy ( BBG ) Putin’s Ukraine Gambit Hurts Economy as Allies Lose Billions  ( ...
Frontrunning: February 25 [Published Zero Hedge - Feb 25 2014]
Turkish PM says tapes of talk with son a fabrication ( Reuters ) but opposition confirms authenticity, and national TV carriers cut parliament when played live Inside the Showdown Atop Pimco, the World's Biggest Bond Firm ( WSJ ) Ex-Jefferies Trader’s ...
Week’s Option Activity (1/13 ~ 1/28) [Published Chimera Research Group - Proceed With Confidence - Jan 28 2014]
The following stocks had notable activity in their options during the past week(s): $XOMA (1/13): 2,550 JUN risk reversals were purchased (stock at $8.32) for 0.40 or $102,000. 2,550. The post Week’s Option Activity (1/13 ~ 1/28) appeared first on ...
1 2

Press Releases

sort by: Date | Relevance
The Zacks Analyst Blog Highlights: Sanofi, Rege... [Published Financial Services - Mar 13 2014]
Technical Roundup - Most Active: J. C. Penney, ... [Published Financial Services - Mar 06 2014]
XOMA Reports 2013 Operational Highlights and Fo... [Published GlobeNewswire: Acquisitions News - Mar 04 2014]
XOMA Provides Update on Gevokizumab Proof-of-Co... [Published GlobeNewswire: Joint Venture News - Mar 04 2014]
XOMA Receives Orphan Drug Designation From U.S.... [Published GlobeNewswire: Acquisitions News - Feb 24 2014]
1 2 3 4
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.